Jefferies Maintains Buy on Novavax, Inc. (NVAX) March 2026

Jefferies maintained its Buy rating on Novavax, Inc. (NVAX) on March 12, 2026. This NVAX analyst rating review reaffirmed confidence in Novavax’s capital-light adjuvant platform and improving line of sight. The note did not post a price target. Jefferies cited platform strength as the rationale in its research note reported by StreetInsider.